Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the firm's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $52.76, for a total value of $371,430.40. Following the completion of the sale, the chief executive officer directly owned 74,760 shares of the company's stock, valued at $3,944,337.60. This trade represents a 8.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jack Bendheim also recently made the following trade(s):
- On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $55.91, for a total value of $393,606.40.
- On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total value of $382,201.60.
- On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total value of $384,665.60.
- On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total value of $415,923.20.
- On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
- On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
- On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total value of $272,764.80.
- On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.
- On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
- On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
Phibro Animal Health Stock Up 1.3%
PAHC stock opened at $53.18 on Friday. Phibro Animal Health Corporation has a twelve month low of $18.33 and a twelve month high of $60.08. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The stock's 50 day moving average is $53.86 and its 200-day moving average is $46.10. The firm has a market capitalization of $2.16 billion, a PE ratio of 23.64, a P/E/G ratio of 0.81 and a beta of 0.69.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts expect that Phibro Animal Health Corporation will post 3.03 EPS for the current fiscal year.
Phibro Animal Health Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Wednesday, March 4th. Phibro Animal Health's dividend payout ratio (DPR) is currently 21.33%.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Citigroup initiated coverage on Phibro Animal Health in a report on Wednesday, April 15th. They set a "neutral" rating and a $62.00 price target on the stock. Finally, Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $42.40.
Read Our Latest Stock Analysis on Phibro Animal Health
Institutional Trading of Phibro Animal Health
A number of hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC lifted its holdings in Phibro Animal Health by 77.8% during the first quarter. Hsbc Holdings PLC now owns 15,466 shares of the company's stock worth $841,000 after acquiring an additional 6,767 shares during the period. Cvfg LLC bought a new stake in Phibro Animal Health during the first quarter worth $2,962,000. Moran Wealth Management LLC bought a new stake in Phibro Animal Health during the first quarter worth $501,000. Capricorn Fund Managers Ltd lifted its holdings in Phibro Animal Health by 45.1% during the first quarter. Capricorn Fund Managers Ltd now owns 267,045 shares of the company's stock worth $14,770,000 after acquiring an additional 82,944 shares during the period. Finally, Inspire Investing LLC bought a new stake in Phibro Animal Health during the first quarter worth $158,000. 99.34% of the stock is currently owned by institutional investors.
Key Stories Impacting Phibro Animal Health
Here are the key news stories impacting Phibro Animal Health this week:
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
